# A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct02963493/  
OnCo record `nct02963493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Melphalan flufenamide and Dexamethasone in Multiple myeloma, run by Oncopeptides AB, completed.

## Summary

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT02963493 by Oncopeptides AB, with 157 participants recorded, started 2016-12-28 and reaching its primary completion in 2020-10-22. Interventions recorded: Melphalan flufenamide (Melflufen), Dexamethasone. Conditions recorded: Multiple Myeloma.

Linked to the drug Melphalan flufenamide because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02963493
- Phase: 2
- Setting: A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
- Sponsor: Oncopeptides AB
- Enrolled: 157

## Sources

- ClinicalTrials.gov NCT02963493: https://clinicaltrials.gov/study/NCT02963493

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Melphalan flufenamide](https://onco.cc/drugs/melflufen/)
- companies: [Oncopeptides](https://onco.cc/companies/oncopeptides/)

---
JSON: https://onco.cc/api/v1/entities/nct02963493.json